Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2019
Price : $35 *
At a glance
- Drugs Belapectin (Primary) ; Ipilimumab
- Indications Malignant melanoma
- Focus Adverse reactions
- 19 Mar 2019 Status changed from active, no longer recruiting to completed.
- 03 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting.